Tirzepatide 15mg
Dual GLP-1/GIP Agonist for Superior Weight Loss Research
Tirzepatide (Mounjaro/Zepbound) is the first dual GLP-1/GIP receptor agonist, achieving 20-22% weight loss in SURMOUNT trials — surpassing semaglutide. FDA-approved for both diabetes and obesity, it represents the next generation of metabolic peptide research.
Dual GLP-1/GIP Agonist for Superior Weight Loss Research
Tirzepatide activates both GLP-1R and GIPR, leveraging GIP's complementary mechanisms — including increased insulin sensitivity, improved fat storage regulation, and enhanced satiety via ventromedial hypothalamus pathways — to achieve superior metabolic outcomes vs. GLP-1 monotherapy.
As one of the most studied compounds in the metabolic & fat loss research space, Tirzepatide has attracted sustained scientific interest across Weight loss mechanism research, Dual incretin receptor studies, Diabetes and obesity research. Peer-reviewed evidence indicates that 20-22% weight loss in SURMOUNT-1 — best approved weight loss data, which has positioned Tirzepatide as a reference standard for researchers exploring weight loss mechanism research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Tirzepatide Documented Benefits: 4 Documented Mechanisms
Superior Weight Loss
20-22% body weight reduction in SURMOUNT-1 trial, outperforming semaglutide in head-to-head studies.
Dual Receptor Mechanism
GLP-1R + GIPR co-agonism provides complementary appetite suppression and metabolic improvement pathways.
FDA Approval
Approved as Mounjaro (T2D) and Zepbound (obesity), the best-in-class incretin therapy.
Cardiovascular Benefits
SURPASS-CVOT trial data shows cardiovascular risk reduction comparable to semaglutide.
How Tirzepatide Works: Molecular Mechanism & Pathway
Dual GLP-1R/GIPR agonist activating complementary incretin pathways; GLP-1R for appetite suppression and insulin secretion; GIPR for enhanced fat metabolism and insulin sensitivity.
The 4 primary research pathways identified for Tirzepatide — Superior Weight Loss, Dual Receptor Mechanism, FDA Approval — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that outperforms semaglutide in SURMOUNT-5 head-to-head, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Tirzepatide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Tirzepatide is routinely studied alongside Semaglutide and Tirzepatide in metabolic & fat loss-focused compound panels. Researchers investigating weight loss mechanism research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that fDA-approved Mounjaro/Zepbound has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Tirzepatide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- 20-22% weight loss in SURMOUNT-1 — best approved weight loss data
- Outperforms semaglutide in SURMOUNT-5 head-to-head
- FDA-approved Mounjaro/Zepbound
Ideal For
- Weight loss mechanism research
- Dual incretin receptor studies
- Diabetes and obesity research
- Metabolic syndrome investigation
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Tirzepatide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
20-22% weight loss in SURMOUNT-1 — best approved weight loss data
Outperforms semaglutide in SURMOUNT-5 head-to-head
FDA-approved Mounjaro/Zepbound
Third-Party Verified Every Batch
Each vial of Tirzepatide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
